Skip to Content

What is the difference between Cyltezo and Humira?

Answers (1)

Official Answer by 10 Oct 2017

Cyltezo (adalimumab-adbm), from Boehringer Ingelheim, is a biosimilar to Humira (adalimumab). Both are anti-TNF-α monoclonal antibodies. A biosimilar, according to the FDA, is a biological product that is highly similar to an FDA-approved biological product, known as a reference product (in this case Humira), and has no clinically meaningful differences in terms of safety and effectiveness.

Both biologics are used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis, and plaque psoriasis. Cyltezo is not an interchangeable product with Humira; the physician must write a prescription specifically for Cyltezo.

See also: free discount card

Further Information

Search for questions

Still looking for answers? Try searching for what you seek or ask your own question.

Frequently Asked Questions

What disease is Elzonris (tagraxofusp-erzs) used to treat?

Updated 7 Jan 2019 1 answerFAQ by

How do you use the ProAir Digihaler?

Updated 7 Jan 2019 1 answerFAQ by

How many biosimilars have been approved in the United States?

Updated 8 Jan 2019 1 answerFAQ by

What are the brands of sumatriptan?

Updated 19 days ago 1 answerFAQ by

What is botulinum toxin used to treat?

Updated 10 days ago 1 answerFAQ by